These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6827733)

  • 1. New anticancer drug class.
    Fuerst ML
    JAMA; 1983 Mar; 249(12):1539, 1543. PubMed ID: 6827733
    [No Abstract]   [Full Text] [Related]  

  • 2. [New antineoplastic drugs of the podophyllotoxin derivative group].
    Robak T; Płuzańska A
    Pol Tyg Lek; 1983 Jan; 38(1):27-30. PubMed ID: 6346283
    [No Abstract]   [Full Text] [Related]  

  • 3. The podophyllotoxin derivatives VP16-213 and VM26.
    Issell BF
    Cancer Chemother Pharmacol; 1982; 7(2-3):73-80. PubMed ID: 7044593
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment strategies in relation to drug action.
    Muggia FM; McVie G
    NCI Monogr; 1987; (4):129-33. PubMed ID: 2819724
    [No Abstract]   [Full Text] [Related]  

  • 5. Etoposide and teniposide in the treatment of acute leukemia.
    Björkholm M
    Med Oncol Tumor Pharmacother; 1990; 7(1):3-10. PubMed ID: 2187120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Podophyllotoxin derivatives.
    D'Incalci M; Garattini S
    Cancer Chemother Biol Response Modif; 1991; 12():75-81. PubMed ID: 1931460
    [No Abstract]   [Full Text] [Related]  

  • 7. The epipodophyllotoxin derivatives VM26 and VP16: experimental and clinical aspects.
    Dombernowsky P; Hansen HH
    Eur J Haematol Suppl; 1988; 48():49-57. PubMed ID: 3073960
    [No Abstract]   [Full Text] [Related]  

  • 8. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphomas, and other malignancies.
    Radice PA; Bunn PA; Ihde DC
    Cancer Treat Rep; 1979 Aug; 63(8):1231-9. PubMed ID: 225026
    [No Abstract]   [Full Text] [Related]  

  • 9. Podophyllotoxins for brain metastases of small cell lung cancer.
    Haaxma-Reiche H; Berendsen HH; Postmus PE
    J Neurooncol; 1988 Nov; 6(3):231-2. PubMed ID: 2852221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimetastasis effect of two derivatives of epiposophyllotoxin in mice.
    Cattan A; Pourny C; Carpentier Y; Cattan E; Barouh M
    Eur J Cancer (1965); 1976 Oct; 12(10):797-805. PubMed ID: 976288
    [No Abstract]   [Full Text] [Related]  

  • 11. Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213.
    Rivera G; Avery T; Roberts DW
    Eur J Cancer (1965); 1975 Sep; 11(9):639-47. PubMed ID: 1220978
    [No Abstract]   [Full Text] [Related]  

  • 12. Teniposide: a review of 12 years of experience.
    O'Dwyer PJ; Alonso MT; Leyland-Jones B; Marsoni S
    Cancer Treat Rep; 1984 Dec; 68(12):1455-66. PubMed ID: 6391663
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro antitumor activity of teniposide against carcinoma of the lung in human tumor clonogenic assay.
    Matsushima Y; Kanzawa F; Miyazawa N; Sasaki Y; Saijo N
    Anticancer Res; 1986; 6(5):921-4. PubMed ID: 3026235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. VM26: phase I and II studies.
    Macbeth FR
    Cancer Chemother Pharmacol; 1982; 7(2-3):87-91. PubMed ID: 7044595
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II study of VM-26 in adult malignancies.
    Spremulli E; Schulz JJ; Speckhart VJ; Wampler GL
    Cancer Treat Rep; 1980 Jan; 64(1):147-9. PubMed ID: 7379049
    [No Abstract]   [Full Text] [Related]  

  • 16. 4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations.
    Rivera G; Avery T; Pratt C
    Cancer Chemother Rep; 1975; 59(4):743-9. PubMed ID: 1100225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of teniposide in small cell carcinoma of the lung.
    Pedersen AG; Bork E; Osterlind K; Dombernowsky P; Hansen HH
    Cancer Treat Rep; 1984 Oct; 68(10):1289-91. PubMed ID: 6098366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etoposide: four decades of development of a topoisomerase II inhibitor.
    Hande KR
    Eur J Cancer; 1998 Sep; 34(10):1514-21. PubMed ID: 9893622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase I trial and pharmacokinetics of VM 26 combined with cisplatin administered by the intraperitoneal route without mixing time].
    Chatelut E; Canal P; De Forni M; Chevreau C; Houin G; Bugat R
    Bull Cancer; 1989; 76(8):893-6. PubMed ID: 2620120
    [No Abstract]   [Full Text] [Related]  

  • 20. Teniposide in refractory ovarian cancer: a phase II study.
    Sessa C; D'Incalci M; Landoni F; Colombo N; Mangioni C
    Cancer Treat Rep; 1984 May; 68(5):815-6. PubMed ID: 6722838
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.